Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTIH study of oral POLQ inhibitor GSK4524101 with niraparib in solid tumors
2024-520197-36-00Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2025
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 16
01
Overview
Phase 2, open-label trial of IDE705 and niraparib in Nonhematologic neoplasms and breast cancer (2 arms), sponsored by GSK. Primary endpoints: Part 1 - Proportion of participants with dose limiting toxicities (DLTs), Part 1 - Proportion of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) based on severity and 4 more. Started Nov 2025; status: completed.
02
Drugs
IDE705niraparib
03
Conditions
Nonhematologic neoplasmsbreast cancer
Beyond the preview
Go deeper on 2024-520197-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520197-36-00.